Lunch Program: Strengthening CHD Care: Evolving Product Design and Lifetime Management Considerations
Sponsored by Edwards Lifesciences.
Join us as we discuss the evolution of the Edwards SAPIEN 3 Pulmonic Portfolio and its role in addressing the complex needs of patients with congenital heart disease. Using case-based discussion, long-term COMPASSION S3 data and ALTERRA trial results, we’ll review valve performance, durability considerations, procedural strategies and outcomes relevant to TPVR with SAPIEN 3. The session will highlight the latest enhancements to the SAPIEN 3 Transcatheter Pulmonic Valve Delivery System, including design updates for precise valve alignment and expanded options for valve
positioning. This discussion will focus on lifetime RVOT management and why SAPIEN 3 technology remains essential.